Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fatality

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Fatality. Displaying page 1 of 1.
    EudraCT Number: 2018-000005-23 Sponsor Protocol Number: Ghreline Start Date*: 2018-12-12
    Sponsor Name:University of Twente
    Full Title: Ghrelin treatment of comatose patients after cardiac arrest: A clinical trial to promote cerebral recovery
    Medical condition: Brain damage after cardiac arrest
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000343-26 Sponsor Protocol Number: ULTRA12 Start Date*: 2012-09-06
    Sponsor Name:Academic Medical Center, Neurosurgery
    Full Title: Ultra-early tranexamic acid after subarachnoid hemorrhage. A prospective, randomized, multicenter study.
    Medical condition: subarachnoid hemorrhage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001904-12 Sponsor Protocol Number: 18040 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Nottingham
    Full Title: Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH)
    Medical condition: Intracerebral haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10019016 Haemorrhagic stroke PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-003176-38 Sponsor Protocol Number: 135.312 Start Date*: 2006-05-22
    Sponsor Name:Boehringer Ingelheim Pharma Ges mbH
    Full Title: A placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4 hours 30 minutes after stroke onset
    Medical condition: Ischemic stroke 3 and 4 hours 30 minutes before treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-001438-25 Sponsor Protocol Number: VWM1 Start Date*: 2020-04-21
    Sponsor Name:VU University Medical Center
    Full Title: A Study to Explore the Safety, Tolerability, Pharmacokinetic Profile, and Potential Efficacy of Guanabenz in Patients With Early Childhood Onset Vanishing White Matter (VWM)
    Medical condition: Vanishing white matter
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001370-30 Sponsor Protocol Number: CACZ885D2310 Start Date*: 2020-04-29
    Sponsor Name:Novartis Pharma AG
    Full Title: Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CA...
    Medical condition: COVID-19-induced pneumonia (CAN-COVID)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002546-36 Sponsor Protocol Number: 2018-002546-36 Start Date*: 2020-03-10
    Sponsor Name:Oslo University Hospital
    Full Title: TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A PROSPECTIVE, RANDOMIZED-CONTROLLED, DOUBLE-DUMMY, DOUBLE-BLIND PHASE 3 MULTI-CENTRE TRIAL OF TNK 0.25 MG/KG + PLACEBO VS. ASA...
    Medical condition: Central retinal artery occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) LT (Completed) FI (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001310-38 Sponsor Protocol Number: CAPSID2020-DRK-BSD Start Date*: 2020-04-06
    Sponsor Name:DRK-Bluspendedienst Baden-Württemberg - Hessen gGmbH
    Full Title: A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19
    Medical condition: Patients with SARS-CoV-2 infection and: 1. age ≥ 18 years and ≤ 75 years 2. SARS-CoV-2 infection confirmed by PCR (BAL, sputum, nasal and/or pharyngeal swap) 3. severe disease ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10047475 Viral pneumonia, unspecified LLT
    23.0 100000004848 10070267 SARS virus test positive LLT
    20.0 100000004865 10021433 Immunization LLT
    21.1 100000004865 10054540 Passive immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2013-000228-33 Sponsor Protocol Number: GN12NE462 Start Date*: 2013-11-07
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. The University of Glasgow
    Full Title: Inhibition of complement activation (eculizumab®) in Guillain-Barré Syndrome study
    Medical condition: Guillain-Barré Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10018766 Guillain Barre syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001476-37 Sponsor Protocol Number: HUB-INF-BEATLE-403 Start Date*: 2019-04-24
    Sponsor Name:Dra. Carlota Gudiol González. Servicio de Enfermedades Infecciosas. Hospital Universitari de Bellvitge.
    Full Title: Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in hematologic patients (BEATLE study).
    Medical condition: Febrile neutropenia is the presence of fever in compramised immune activity in patients with hematologic disease. In which case, an antibiotic must be started.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10029357 Neutropenia malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005299-42 Sponsor Protocol Number: 2006-03 Start Date*: 2007-05-16
    Sponsor Name:GETAID
    Full Title: A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study)
    Medical condition: - Diagnosis of UC according to Lennard-Jones criteria - Endoscopically demonstrated colorectal lesions localized above the anal margin and extending at least up to 15cm proximally. - Severe acute ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045282 UC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) FI (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001795-15 Sponsor Protocol Number: COMBAT-19 Start Date*: 2020-05-07
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyperinflammation: the COMBAT-19 trial
    Medical condition: Respiratory failure during COVID-19 pneumonia and hyperinflammation
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001254-22 Sponsor Protocol Number: SARPAC Start Date*: 2020-03-24
    Sponsor Name:University Hospital Ghent
    Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit...
    Medical condition: Acute hypoxic respiratory failure of COVID-19 patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10074615 Hypoxic respiratory failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004505-16 Sponsor Protocol Number: CONVINCE Start Date*: 2016-08-08
    Sponsor Name:University College Dublin
    Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke
    Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10044376 Transient cerebrovascular events HLT
    20.0 100000004866 10008205 Cerebrovascular embolism and thrombosis HLT
    22.1 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10029205 - Nervous system disorders 10007962 Central nervous system vascular disorders NEC HLT
    20.0 10029205 - Nervous system disorders 10007963 Central nervous system vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Nov 04 01:34:41 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA